{"analyses":[{"groupDescription":"Null hypothesis of ORR by BICR for cohort A was 30%.","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Exact binominal"},{"groupDescription":"Null hypothesis of ORR by BICR for cohort B was 15%.","groupIds":["OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Exact binominal"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.8","upperLimit":"69.6","value":"61.0"},{"groupId":"OG001","lowerLimit":"22.9","upperLimit":"47.3","value":"34.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"description":"ORR: % of participants with best overall response of confirmed stringent complete response (sCR), CR, very good partial response (VGPR) or PR per IMWG criteria. sCR: CR \\& normal serum free light chain (sFLC) ratio \\& absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \\& urine, disappearance of any soft tissue plasmacytoma \\& \\<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum \\& urine M-protein detectable by immunofixation but not on electrophoresis; or \\>=90% reduction in serum M-protein \\& urine M-protein level \\<100mg/24h. PR: \\>=50% reduction in serum M-protein \\& reduction in 24h urinary M-protein by \\>=90% or \\<200 mg/24h. If serum \\& urine M-protein were unmeasurable, VGPR \\& PR: \\>=90% \\& \\>=50% decrease in difference respectively between involved \\& uninvolved sFLC levels \\& if present at baseline, \\>=90% \\& \\>=50% reduction in soft tissue plasmacytomas' size.","dispersionType":"95% Confidence Interval","groups":[{"description":"BCMA-naïve participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.","id":"OG000","title":"Cohort A"},{"description":"BCMA-exposed participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.","id":"OG001","title":"Cohort B"}],"paramType":"NUMBER","populationDescription":"Safety analysis set in each cohort included all enrolled participants in the respective cohort who received at least one dose of study intervention.","reportingStatus":"POSTED","timeFrame":"From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months)","title":"Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}